Compare MCFT & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MCFT | CMPS |
|---|---|---|
| Founded | 1968 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 578.7M | 1.9B |
| IPO Year | 2015 | 2020 |
| Metric | MCFT | CMPS |
|---|---|---|
| Price | $19.55 | $13.73 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | $24.25 | ★ $25.38 |
| AVG Volume (30 Days) | 209.4K | ★ 2.3M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $348,903,000.00 | N/A |
| Revenue This Year | $9.18 | N/A |
| Revenue Next Year | $8.23 | N/A |
| P/E Ratio | $59.52 | ★ N/A |
| Revenue Growth | ★ 22.77 | N/A |
| 52 Week Low | $17.19 | $4.82 |
| 52 Week High | $28.44 | $15.87 |
| Indicator | MCFT | CMPS |
|---|---|---|
| Relative Strength Index (RSI) | 28.94 | 57.43 |
| Support Level | $18.92 | $12.95 |
| Resistance Level | $25.62 | $14.87 |
| Average True Range (ATR) | 1.17 | 0.74 |
| MACD | -0.47 | 0.03 |
| Stochastic Oscillator | 10.05 | 57.71 |
MasterCraft Boat Holdings Inc designs, manufactures, and markets performance sport boats and outboard boats. The company is based in the United States and operates in three brand-specific segments. The MasterCraft segment generates the majority of the company's revenue and includes inboard boats for water skiing, wakeboarding, and wake surfing. The Pontoon segment produces pontoon boats at its Owosso, Michigan facility. Pontoon boats are used for general recreational boating. The Aviara segment produces luxury day boats at its Merritt Island, Florida facility. Aviara boats are used for general recreational boating.
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.